# Management of Methicillin-Resistant Staphylococcus Aureus Otitis

Presentor: R1 蔡典倫

Supervisor: Dr 黃啟原

### Introduction

- Methicillin-resistant Staphylococcus aureus (MRSA) was initially detected in England in the 1960s
- Two strains
  - Community-associated strains (CA-MRSA):
     susceptible to commonly available antibiotics
  - Hospital-associated strains (HA-MRSA):
     multiple drug resistance, including vancomycin
- MRSA was isolated in 24% of specimens from suppurative otitis media in nationwide survey in Japan, November 1998 - March 1999

## Epidemiology

- Of cultures of ear infections:
  - MRSA: average in 7.0% (range 0.3 24.8%)
  - MSSA: average in 18.3% (range 9.6 32.1%)
  - Pseudomonas aeruginosa: in 36.6% (range 13.5)
    - -48.6%

### Risk Factor - CA-MRSA infection

Previous MRSA infection or colonization

Residents of residential care facilities

Injection drug users

Patients who are HIV positive

Men who have sex with men

Patients with chronic skin disorders

Recurrent or recent antibiotic use

Low socioeconomic status

### Risk Factor - HA-MRSA infection

Hospitalization (overnight) in past 12 months

Surgery in past 12 months

Dialysis

Renal failure

Indwelling catheter or medical device

Residence in long-term care facility

Known colonization with MRSA in past 12 months

- 1. Journal of Antimicrobial Chemotherapy 2003;52:533–4
- 2. Journal of Hospital Infection 2006;63(Suppl 1):S1-44

## Management

- Systemic antibiotic treatment
  - Parenteral therapy
  - Oral therapy
- Topical treatment
- Cleaning & Irrigation
- Surgery

Systemic treatment

## Concerning of antibiotic efficacy

- Current measure of efficacy of antibiotics: minimal inhibitory concentration (MIC) levels
- However, MIC is reflective of serum levels of antibiotics but not tissue levels

## Systemic treatment

### Oral form in skin & soft tissue infection

| Treatment                         | Adult dose   | Pediatric dose   |  |
|-----------------------------------|--|--|--|
| Clindamycin                       | 300 to 450 mg orally three times daily             | 40 mg/kg/day in 3 or 4 doses                                       |  |
| Trimethoprim-<br>sulfamethoxazole | 1 DS tab orally twice daily                        | 8 to 12 mg trimethoprim component/kg /day in 2 doses               |  |
| Doxycycline                       | 100 mg orally twice daily                          | ≤45 kg: 4 mg/kg/day in 2 doses >45 kg: 100 mg in 2doase            |  |
| Minocycline                       | 200 mg orally once, then 100 mg orally twice daily | 4 mg/kg once, then 4 mg/kg/day in 2 doses                          |  |
| Linezolid                         | 600 mg orally twice daily                          | <12 years: 30 mg/kg/day in 3 doses<br>≥12 years: 600 mg in 2 doses |  |
| Tedizolid                         | 200 mg orrally once daily                          |  |  |

### Systemic treatment

Parenteral form in skin & soft tissue infection

| Drug                         | Adult dose                                 |  |
|------------------------------|--|--|
| Vancomycin                   | 15-20 mg/kg/dose Q8-12H, max: 2 g per dose |  |
| Daptomycin                   |  |  |
| Skin & soft tissue infection | 4 mg/kg IV once daily                      |  |
| Bacteremia                   | 6 mg/kg IV once daily                      |  |
| Linezolid                    | 600 mg IV (or orally) twice daily          |  |
| Ceftaroline                  | 600 mg IV Q12H                             |  |
| Tigecycline                  | 100 mg IV once, then 50 mg IV Q12H         |  |

- 1. Clinical Infectious Diseases , vol 49, 2009: pp177-80
- 2. Journal of Antimicrobial Chemotherapy, vol50, 2006:pp 3245-3249
- 3. Clinical Infectious Diseases, vol 52, No3, 2011:pp 285-292

### Guideline of antibiotics for otitis?

 Guidelines for management of MRSA infections of skin and soft tissue had been established, but none for ear

### Effective Treatment For Otitis from Literatures

Parentral form
 Vancomycin: alone or combination to other agents

Oral form

Linezoid: alone

TMP-SMX: alone or combination to other agents

Vancomycin Mupirocin Chloramphenicol

J Laryngol Otol. 2004 Aug;118(8):645-7.

## Topical vancomycin for chronic suppurative otitis media with methicillin-resistant Staphylococcus aureus otorrhoea.

Jang CH, Song CH, Wang PC.

Department of Otolaryngology, Wonkwang University Hospital, Wonkwang Medical School, Iksan, Korea. chulsavio@hanmail.net

- 55 chronic suppurative otitis media(CSOM) with MRSA otorrhea patients
- Treatment :
  - 35 patients with topical Vancomycin (25mg/ml), 2 drops (0.8 mg)
     3 times daily for 10 days
  - 20 patients with topical gentamicin 0.3%, 2 drops 3 times daily for 10 days
- Result:
  - Vancomycin eardrops are effective in patients with MRSA otorrhea
  - No statistically significant difference in mean bone conduction thresholds after topical treatment

|   |          | Outcome, n (%)    |                 |                  |
|---|----------|-------------------|-----------------|------------------|
| Group                                   | Ears (n) | Cure              | Improvement     | Failure          |
| Vancomycin*<br>Gentamicin               | 35<br>20 | 30 (85)<br>2 (10) | 3 (8)<br>2 (10) | 2 (5)<br>16 (80) |
| * $p < 0.03$ , vancomycin vs gentamicin |          |                   |                 |                  |

Otol Neurotol. 2008 Aug;29(5):676-8. doi: 10.1097/MAO.0b013e31817ef4b7.

# Clinical effectiveness of ototopical application of mupirocin ointment in methicillin-resistant Staphylococcus aureus otorrhea.

Furukawa M, Minekawa A, Haruyama T, Narui Y, Sugita G, Sugita R, Kusunoki T, Ikeda K.

Department of Otorhinolaryngology, Juntendo University School of Medicine, Tokyo, Japan.

- February 2006 January 2007, 26 patients(13 COM & 13 post-operation) with MRSA otorrhea
- Treatment:
  - 16 patients with topical Mupirocin, 0.6gm 1-4 times for 2-3 weeks
  - 10 patients with ofloxacin ear drops, daily for 2 3 weeks
- Result:
  - Mupirocin are effective in patients with MRSA otorrhea
  - No significant difference in mean bone conduction thresholds after topical treatment

| No.                    |          | Outcome (%)        |                 |                 |  |
|------------------------|----------|--------------------|-----------------|-----------------|--|
| Group                  | ears     | Cure               | Improvement     | Failure         |  |
| Mupirocin<br>Ofloxacin | 18<br>10 | 18 (100)<br>2 (20) | 0 (0)<br>2 (20) | 0 (0)<br>6 (60) |  |

Arch Otolaryngol Head Neck Surg. 2000 Dec;126(12):1440-3.

## Methicillin-resistant Staphylococcus aureus otorrhea after tympanostomy tube placement: an emerging concern.

Hartnick CJ, Shott S, Willging JP, Myer CM 3rd.

Department of Pediatric Otolaryngology, Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229, USA. harq4k@chmcc.org

- December 1998-January 2000, 8 patients, ages of 1-11 years with COM and MRSA otorrhea
- Treatment & response :
  - Ciprofloxacin: 0/2
  - Chloramphenicol: 3/3
  - Tobramycin: 3/3

### Possible Effective Alternative Topical Agents

• Fusidic acid Clinical Otolaryngology and Allied Sciences 2001;26: 218–20 The Journal of Laryngology & Otology 2006;120:63–4

Gentamicin Archives of Otolaryngology - Head and Neck Surgery
 2005;131: 782–4

• Gentian violet Journal of Otolaryngology 2006;35:384–6

 Biofilms are the likely cause of CSOM & may resistance to antibiotic therapy

 Acetic acid including Burow's solution had a destructive effect on the biofilm of pathogens

1.ENT: Ear, Nose & Throat Journal Aug 2002 Supplement 1, Vol. 81 Issue 8, p8-10

2. Archives of Dermatological Research 1999;/291:/570 3.


Acta Otolaryngol. 2010;130(1):42-6. doi: 10.3109/00016480902870522.

## The appropriate medical management of methicillin-resistant Staphylococcus aureus in chronic suppurative otitis media.

Choi HG, Park KH, Park SN, Jun BC, Lee DH, Yeo SW.

Department of Otolaryngology HNS, College of Medicine, Catholic University of Korea, Seoul, Korea.

- January 2005 July 2008 of 85 patients with otorrhoea caused by CSOM, retrospectively
- Treatment modalities:
  - Aural cleansing & irrigation with diluted acetic acids
     (2 ml) (50 cases)
  - Intravenous Teicoplanin, 4 mg/kg (22 cases)
  - Intravenous Vancomycin, 20 mg/kg (15 cases)
- Result: no significant differences between the 3 groups



Auris Nasus Larynx. 2007 Mar;34(1):9-13. Epub 2006 Aug 21.

## Efficacy of mastoidectomy on MRSA-infected chronic otitis media with tympanic membrane perforation.

Mutoh T, Adachi O, Tsuji K, Okunaka M, Sakagami M.

Department of Otolaryngology, Hyogo College of Medicine, 1-1 Mukogawa, Nishinomiya City, Hyogo 663-8501, Japan. mutochin@hyo-med.ac.jp

- January 1998 October 2003, 18 ears with surgery for MRSA-infected COM, 33 ears with surgery for MSSAinfected COM, retrospectively
- Treatment: tympanoplasty + mastoidectomy or tympanoplasty only
- Result: Mastoidectomy produced better results in discharging ears with MRSA-infected COM

| Characteristics of the patient group |                    |                                 |             |                             |  |
|--------------------------------------|--------------------|---------------------------------|-------------|-----------------------------|--|
|                                      |                    | Total number of ears (patients) | M/F ratio   | Average age in year (range) | Discharging /dry<br>ears<br>at operation |
|                                      | Mastoidectomy      | 10(9)                           | 3/7(0.43)   | 50.1(7-64)                  | 9/1                                      |
| MRSA                                 | Non-mastoidectomy  | 8(8)                            | 4/4(1.00)   | 47.3(6-64)                  | 4/4                                      |
|                                      | Total              | 18(15)                          | 7/11(0.64)  | 48.9(6-64)                  | 13/5                                     |
|                                      | Mastoidectomy      | 11(10)                          | 4/7(0.57)   | 49.0(32-71)                 | 11/0                                     |
| MSSA                                 | Non- mastoidectomy | 20(19)                          | 7/13(0.54)  | 47.3(5-73)                  | 15/5                                     |
|                                      | Total              | 31(28)                          | 11/20(0.55) | 47.9(6-64)                  | 26/5                                     |

| Graft success rates |   |   |                                     |   |
|---------------------|---|---|-------------------------------------|---|
|                     |   | Discharging                                 | Dry                                 | Total                                       |
| MRSA                | Mastoidectomy  Non-mastoidectomy  Total | 8/9(88.9%)<br>1/4(25.0%)<br>9/13(69.2%)     | 1/1(100%)<br>4/4(100%)<br>5/5(100%) | 9/10(90.0%)<br>5/8(62.5%)<br>14/18(77.8%)   |
| MSSA                | Mastoidectomy Non-mastoidectomy Total   | 9/11(81.8%)<br>12/15(80.0%)<br>21/26(80.8%) | 4/5(80.0%)<br>4/5(80.0%)            | 9/11(81.8%)<br>16/20(80.0%)<br>25/31(80.6%) |

Acta Otolaryngol. 2002 Dec;122(8):827-30.

## Community-acquired methicillin-resistant Staphylococcus aureus infections in discharging ears.

Hwang JH, Tsai HY, Liu TC.

Department of Otolaryngology, Poh-Ai Hospital, Lotung, Taiwan.

 August 2000 - February 2002, 248 isolates recovered from 221 discharging ears of patients

- Of cultures of ear infections:
  - MRSA: average in 12.2%
  - MSSA: average in 32.1%
  - Pseudomonas aeruginosa: in 34.4%

| Dathagan |           | ļ         | Age (years) |           |           |
|----------|-----------|-----------|-------------|-----------|-----------|
| Pathogen | < 20      | 21–40     | 41–60       | >61       | Total     |
| MRSA     | 1 (3.7)   | 4 (14.8)  | 8 (29.6)    | 14 (51.9) | 27 (100)  |
| MSSA     | 7 (9.8)   | 30 (42.3) | 18 (25.4)   | 16 (22.5) | 71 (100)  |
| Non-SA   | 22 (18.0) | 25 (20.3) | 34 (27.6)   | 42 (34.1) | 123 (100) |

Acta Otolaryngol 2002; 122: 827–830


| Antibiotic   | Susceptibility; n (%) |
|--------------|-----------------------|
| Vancomycin   | 27:27 (100%)          |
| Teicoplanin  | 27:27 (100%)          |
| Minocycline  | 26:27 (96.3%)         |
| Fusidic acid | 26:27 (96.3%)         |
| Gentamicin   | 10:27 (37.0%)         |
| Clindamycin  | 4:27 (14.8%)          |
| Erythromycin | 3:27 (11.1%)          |

Acta Otolaryngol 2002; 122: 827–830

## Conclusion

- Systemic treatment
  - Parenteral therapy: Vancomycin: alone or with others
  - Oral therapy: Linezoid: alone
     TMP-SMX: alone or with others
- Topical treatment
  - Vancomycin ear drops
  - Mupirocin ointment
  - Chloramphenicol ear drops
- Cleaning & Irrigation
  - Diluted acetic acids

- Surgery
  - Tympanomastoidectomy



Thanks for your listening